The role of upadacitinib for the treatment of axial spondyloarthritis-Reference-Cited by-同舟云学术

The role of upadacitinib for the treatment of axial spondyloarthritis

Published:2023-10 Issue:15 Volume:15 Page:1227-1237
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

George Navya¹,Liew Jean W²^ORCID,Dubreuil Maureen²³^ORCID

Affiliation:

1. Internal Medicine Residency Program, Boston University Medical Center, Boston, MA 02118, USA

2. Section of Rheumatology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA

3. VA Boston Healthcare System, Boston, MA 02130, USA

Abstract

Janus kinase inhibitors were recently approved for treatment of axial spondyloarthritis following clinical trials demonstrating benefit for symptom control. Upadacitinib treatment resulted in Assessment of SpondyloArthritis International Society 40 response improvement (defined as at least 40% improvement and an absolute improvement in global assessment of disease activity, patient assessment of back pain and other indices) in 45–52% of trial participants with axial spondyloarthritis. We review the data for efficacy and safety of upadacitinib in this patient population.

Funder

Rheumatology Research Foundation

Doris Duke Charitable Foundation

Spondylitis Association of America

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2023-0032

Reference41 articles.

1. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria

2. Evaluation of Diagnostic Criteria for Ankylosing Spondylitis

3. Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis

4. Spondylitis Association of America. Upadacitinib (Rinvoq) approved for non-radiographic axial spondyloarthritis (2022). https://spondylitis.org/research-new/upadacitinib-rinvoq-approved-for-non-radiographic-axial-spondyloarthritis/#:∼:text=Upadacitinib%20(Rinvoq)%20has%20become%20the,nr%2DaxSpA)%20in%20adults.&text=Upadacitinib%20was%20also%20approved%20for,PsA)%20in%20December%20of%202021

5. Treatment of axial spondyloarthritis: an update

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease;Immunotherapy;2024-02-16

2. Welcome to Immunotherapy Volume 16!;Immunotherapy;2024-01